本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有限公司（以下简 称"津药和平"） 注射用甲泼尼龙琥珀酸钠（以下简称"该药品"）获得巴拿马共和国卫生部注册证书 （标志着可以生产并在巴拿马共和国市场销售该产品），现将相关信息公告如下： 一、药品的基本情况 1.药品名称：注射用甲泼尼龙琥珀酸钠 2.剂型：注射用冻干粉针剂 3.规格：500mg 4.持有人：津药和平（天津）制药有限公司 5.批准文号：210124 三、对上市公司影响及风险提示 津药和平注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书，将为制剂业务拓展巴拿马市场带 来新机遇，也将进一步推动公司国际化战略布局。由于该药品在国外市场销售的时间、市场规模、后续 拓展进度具有不确定性，加之药品出口业务容易受到国外市场环境变化、汇率波动等因素影响，敬请广 大投资者理性投资，注意防范投资风险。 特此公告。 津药药业股份有限公司 董事会 2025年11月18日 6.发证机构：巴拿马共和国卫生部 二、药 ...

证券日报网讯 11月18日晚间，津药药业发布公告称，近日，公司子公司津药和平（天津）制药有限公 司注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书（标志着可以生产并在巴拿马共和国市场 销售该产品）。 （编辑 楚丽君） ...

注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治疗、血液疾病和肿 瘤的治疗、休克的治疗等。2024年津药和平向巴拿马共和国卫生部提出注册申请，2025年11月收到卫生 部通知，取得注册证书。根据IQVIA数据库显示，甲泼尼龙类注射剂2023年、2024年全球市场销售额分 别为5.26亿美元、5.21亿美元。 津药和平注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书，将为制剂业务拓展巴拿马市场带 来新机遇，也将进一步推动公司国际化战略布局。 格隆汇11月18日丨津药药业(600488.SH)公布，公司子公司津药和平（天津）制药有限公司注射用甲泼 尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书（标志着可以生产并在巴拿马共和国市场销售该产 品）。药品名称：注射用甲泼尼龙琥珀酸钠，批准文号：210124。 ...

津药药业公告称，近日，其子公司津药和平的注射用甲泼尼龙琥珀酸钠（500mg注射用冻干粉针剂）获 巴拿马共和国卫生部注册证书，可在当地生产销售。该药品是糖皮质激素类药物，用于抗炎等治疗。 2024年提出注册申请，2025年11月取得证书。甲泼尼龙类注射剂2023 - 2024年全球销售额分别为5.26 亿、5.21亿美元。此次获批为公司制剂业务拓展巴拿马市场带来机遇，推动国际化布局，但销售情况有 不确定性。 ...

智通财经APP讯，津药药业(600488.SH)公告，公司子公司津药和平(天津)制药有限公司(简称"津药和 平")注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书(标志着可以生产并在巴拿马共和国市 场销售该产品)。注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治 疗、血液疾病和肿瘤的治疗、休克的治疗等。 ...

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]